Abstract
The successful implementation of artificial intelligence (AI) in healthcare is dependent upon the acceptance of this technology by key stakeholders, particularly patients, who are the primary beneficiaries of AI-driven outcomes. This international, multicenter, cross-sectional study assessed the attitudes of hospital patients towards AI in healthcare across 43 countries. A total of 13806 patients at 74 hospitals were surveyed between February and November 2023, with 64.8% from the Global North and 35.2% from the Global South. The findings indicate a predominantly favorable general view of AI in healthcare, with 57.6% of respondents expressing a positive attitude. However, attitudes exhibited notable variation based on demographic characteristics, health status, and technological literacy. Female respondents and those with poorer health status exhibited fewer positive attitudes towards AI use in medicine. Conversely, higher levels of AI knowledge and frequent use of technology devices were associated with more positive attitudes. It is noteworthy that less than half of the participants expressed positive attitudes regarding all items pertaining to trust in AI. The lowest level of trust was observed for the accuracy of AI in providing information regarding treatment responses. Patients exhibited a strong preference for explainable AI and physician-led decision-making, even if it meant slightly compromised accuracy. This large-scale, multinational study provides a comprehensive perspective on patient attitudes towards AI in healthcare across six continents. Findings suggest a need for tailored AI implementation strategies that consider patient demographics, health status, and preferences for explainable AI and physician oversight. All study data has been made publicly available to encourage replication and further investigation.
Competing Interest Statement
The authors declare the following competing interests: Petros Sountoulides, Keno K Bressem, Renato Cuocolo, Virginia Dignum, Guillermo de Velasco, Alessa Hering, Lili Jiang, George Kolostoumpis, and Alexander Loeser report research grants from the European Commission (101079894); Keno K Bressem reports grants from the Wilhelm Sander Foundation and speaker fees from Canon Medical Systems Corporation and GE Healthcare, and is a member of the advisory board of the EU Horizon 2020 LifeChamps project (875329) and the EU IHI project IMAGIO (101112053); Martina Aineseder reports consultant fees from Segmed, Inc.; Giovanna Ferraioli reports speaker honoraria from Canon Medical Systems, Fujifilm Healthcare, Mindray Healthcare, Philips Healthcare, and Siemens Healthineers, is an advisory board member for Philips Healthcare and Siemens Healthineers and receives royalties from Elsevier; Giovanna Ferraioli's university received equipment grants and unrestricted research grants from Canon Medical Systems, Philips Ultrasound, and Siemens Healthineers. None of the other authors declares potential conflicts of interest.
Funding Statement
This research is funded by the European Union (COMFORT (Computational Models FOR patienT stratification in urologic cancers - Creating robust and trustworthy multimodal AI for health care), project number: 101079894, authors involved: Petros Sountoulides, Renato Cuocolo, Virginia Dignum, Guillermo de Velasco, Alessa Hering, Lili Jiang, George Kolostoumpis, Alexander Loeser, principal investigator: Keno K Bressem, sponsors' website: https://www.comfort-ai.eu). Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union. The European Union cannot be held responsible for them. The funding had no role in the study design, data collection and analysis, manuscript preparation, or decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Charité - Universitätsmedizin Berlin (EA4/213/22), which served as the lead institution, and from all other participating hospitals according to their institutional policies (see eTable 14). Given the unsupervised and anonymous design of the instrument, informed consent was waived to preserve participant anonymity.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† COMFORT consortium members are listed at the end of the manuscript.
Data Availability
The full dataset and data dictionary are publicly available under CC-BY 4.0 international license at figshare.
